# Effects of Empagliflozin + Linagliptin vs Metformin + Insulin Glargine on Renal and Vascular Changes in Type 2 Diabetes

> **NCT02752113** · PHASE3 · COMPLETED · sponsor: **Institut für Pharmakologie und Präventive Medizin** · enrollment: 101 (actual)

## Conditions studied

- Diabetes Mellitus Type 2

## Interventions

- **DRUG:** Empagliflozin and Linagliptin
- **DRUG:** Metformin and Insulin sc

## Key facts

- **NCT ID:** NCT02752113
- **Lead sponsor:** Institut für Pharmakologie und Präventive Medizin
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04
- **Primary completion:** 2018-11-07
- **Final completion:** 2019-05
- **Target enrollment:** 101 (ACTUAL)
- **Last updated:** 2019-07-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02752113

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02752113, "Effects of Empagliflozin + Linagliptin vs Metformin + Insulin Glargine on Renal and Vascular Changes in Type 2 Diabetes". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02752113. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*